As example, the Skip-NMD project18 (10 partners from five countries) aims to restore dystrophin production in a subset of Duchenne muscular dystrophy boys by administration of a drug, which ‘skips’ the mutations causing Duchenne muscular dystrophy. This evidence concerns the gene DMD and Duchenne muscular dystrophy.